Terminated PHASE3 INTERVENTIONAL 2-arm NCT05930938

Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients With Head and Neck Cancer (XXL_2022-01)

A Double-blind, Randomized, Phase III Study of Radiotherapy Combined With cetuXimab + Xevinapant Compared to Radiotherapy Combined With Cetuximab (Standard of Care) + Placebo in Patients With LA SCCHN, Unfit for High-dose Cisplatin

Sponsor: Groupe Oncologie Radiotherapie Tete et Cou

Conditions Squamous Cell Carcinoma of the Head and Neck

Interventions IMRT Placebo Xevinapant cetuximab

Updated 10 times since 2023 Last updated: May 6, 2025 Started: Dec 12, 2023 Primary completion: Sep 30, 2024 Completion: Sep 30, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

toxicity

Other terminated trials from Groupe Oncologie Radiotherapie Tete et Cou

See all terminations from Groupe Oncologie Radiotherapie Tete et Cou

Other Squamous Cell Carcinoma of the Head and Neck trials with similar outcome

Browse all Squamous Cell Carcinoma of the Head and Neck trials

A PHASE3 clinical study on Squamous Cell Carcinoma of the Head and Neck, this trial is terminated or withdrawn. The trial is conducted by Groupe Oncologie Radiotherapie Tete et Cou and has accumulated 10 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

10 versions recorded

Jun 2025 — Present [monthly]

Terminated PHASE3

Status: Completed → Terminated
May 2025 — Jun 2025 [monthly]

Completed PHASE3

Status: Suspended → Completed
Feb 2025 — May 2025 [monthly]

Suspended PHASE3
Oct 2024 — Feb 2025 [monthly]

Suspended PHASE3
Sep 2024 — Oct 2024 [monthly]

Suspended PHASE3

▶ Show 5 earlier versions

Aug 2024 — Sep 2024 [monthly]

Suspended PHASE3

Status: Recruiting → Suspended
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE3
Apr 2024 — Jul 2024 [monthly]

Recruiting PHASE3
Jan 2024 — Apr 2024 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Aug 2023 — Jan 2024 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Groupe Oncologie Radiotherapie Tete et Cou

Data source: Groupe Oncologie Radiotherapie Tete et Cou

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Montbéliard, France